Expression Pattern and Prognostic Value of CTLA-4, CD86, and Tumor-Infiltrating Lymphocytes in Rectal Cancer after Neoadjuvant Chemo(radio)therapy

Yin, Xin-Ke; Wang, Chao; Feng, Lili; Bai, Shao-Mei; Feng, Weixing; Ouyang, Neng-Tai; Chu, Zhonghua; Fan, Xinjuan; Qin, Qiyuan

doi:10.3390/cancers14225573

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A trend towards longer OS was noted for patients with high CTLA-4 and PD-1 expression levels in T-cells. A more recent study assessing CTLA-4 and CD86 expression in TILs in 255 rectal carcinomas previously treated with CRT has provided insights into the role of this immune checkpoint pathway [82]. CTLA-4 and CD86 expression was observed in 69% and 14.1% of cases, respectively.…”

Section: The Ctla-4/cd80-86/cd28 Pathwaymentioning

confidence: 99%

Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review

Koukourakis

Platoni

Tiniakos

et al. 2023

CIMB

View full text Add to dashboard Cite

It is well-established that tumor antigens and molecules expressed and secreted by cancer cells trigger innate and adaptive immune responses. These two types of anti-tumor immunity lead to the infiltration of the tumor’s microenvironment by immune cells with either regulatory or cytotoxic properties. Whether this response is associated with tumor eradication after radiotherapy and chemotherapy or regrowth has been a matter of extensive research through the years, mainly focusing on tumor-infiltrating lymphocytes and monocytes and their subtypes, and the expression of immune checkpoint and other immune-related molecules by both immune and cancer cells in the tumor microenvironment. A literature search has been conducted on studies dealing with the immune response in patients with rectal cancer treated with neoadjuvant radiotherapy or chemoradiotherapy, assessing its impact on locoregional control and survival and underlying the potential role of immunotherapy in the treatment of this cancer subtype. Here, we provide an overview of the interactions between local/systemic anti-tumor immunity, cancer-related immune checkpoint, and other immunological pathways and radiotherapy, and how these affect the prognosis of rectal cancer patients. Chemoradiotherapy induces critical immunological changes in the tumor microenvironment and cancer cells that can be exploited for therapeutic interventions in rectal cancer.

show abstract

Section: The Ctla-4/cd80-86/cd28 Pathwaymentioning

confidence: 99%

Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review

Koukourakis

Platoni

Tiniakos

et al. 2023

CIMB

View full text Add to dashboard Cite

show abstract

Immunophenotype of dendritic cell differentiation markers in breast cancer in in-vitro conditions

Golderova,

Nikolaeva,

Troev

et al. 2023

Russian Journal of Oncology

View full text Add to dashboard Cite

During maturation, dendritic cells begin to synthesize peptides that are MHC-II co-stimulatory molecules CD40, CD80 and CD86, as well as CD83 proteins. In cancer patients, DC dysfunction can lead to serious consequences in the form of deficiency of antitumor immunity, tumor progression, and decreased response to immunotherapy. All this is important to take into account to rethink the tumor immunotherapy strategy. Thus, approaches aimed at enhancing the viability of DCs and preventing their dysfunction and polarization should be considered as a necessary step in the work to increase the effectiveness of DC-based vaccines. The study is conducted to evaluate the expression characteristics of differentiation markers of dendritic cell maturation obtained from peripheral blood monocytes under culture conditions in patients with breast cancer. With informed voluntary consent, 19 patients diagnosed with breast cancer were examined. Mononuclear cells were isolated on a Ficoll density gradient. For adhesion of monocytes to the bottom of culture flasks with a volume of 75 cm2, they were pre-incubated for 1.5 hours in conditions of 5% CO2 at 37˚C. Growth and differentiation factors – GM-CSF (40 µl) and IL-4 (40 µl) – were added to the attached monocytes, which were added on the 1st, 3rd and 5th days of cultivation. Immunophenotyping of dendritic cells was carried out on days 7 and 9 of cultivation using flow cytometry. Flow cytometry data indicate that the viability of cultured dendritic cells in cancer patients is significantly reduced on day 9 compared to day 7 of culture. On day 9, there was a significant increase (p=0.028) in CD80+ expression (2.40 times) and a decrease in CD83+ (1.65 times) compared to day 7 (p=0.036). In general, significant signs of maturation are observed: loss of the monocyte marker CD14, increased expression of CD80+, CD83+, CD86+ - the main markers. A decrease in CD83+ can be considered as a suppression of excessive activation of immune responses. In the future, a more in-depth study of the characteristics of maturation and activation of cultured dendritic cells is necessary to understand the mechanisms and factors influencing the decrease in the effectiveness of immunotherapy with an autologous dendritic cell vaccine.

show abstract

Dendritic cells: the yin and yang in disease progression

Jiménez-Cortegana,

Palomares,

Alba

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity. DCs have been historically considered as the most effective and potent cell population to capture, process and present antigens to activate naïve T cells and originate favorable immune responses in many diseases, such as cancer. However, in the last decades, it has been observed that DCs not only promote beneficial responses, but also drive the initiation and progression of some pathologies, including inflammatory bowel disease (IBD). In line with those notions, different therapeutic approaches have been tested to enhance or impair the concentration and role of the different DC subsets. The blockade of inhibitory pathways to promote DCs or DC-based vaccines have been successfully assessed in cancer, whereas the targeting of DCs to inhibit their functionality has proved to be favorable in IBD. In this review, we (a) described the general role of DCs, (b) explained the DC subsets and their role in immunogenicity, (c) analyzed the role of DCs in cancer and therapeutic approaches to promote immunogenic DCs and (d) analyzed the role of DCs in IBD and therapeutic approaches to reduced DC-induced inflammation. Therefore, we aimed to highlight the “yin-yang” role of DCs to improve the understand of this type of cells in disease progression.

show abstract

Expression Pattern and Prognostic Value of CTLA-4, CD86, and Tumor-Infiltrating Lymphocytes in Rectal Cancer after Neoadjuvant Chemo(radio)therapy

Cited by 3 publications

References 40 publications

Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review

Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review

Immunophenotype of dendritic cell differentiation markers in breast cancer in in-vitro conditions

Dendritic cells: the yin and yang in disease progression

Contact Info

Product

Resources

About